fosaprepitant / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 63 Diseases   25 Trials   25 Trials   493 News 


«1234567»
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Retrospective data, Review, Journal:  Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. (Pubmed Central) -  Jul 24, 2022   
    As indicated by our findings, several studies identified low albumin as a risk factor for ifosfamide-induced encephalopathy. However, further clinical studies with a larger population of patients are required to evaluate the clinical significance of ifosfamide-related neurotoxicity and aprepitant or fosaprepitant.
  • ||||||||||  fosaprepitant / Generic mfg.
    Trial completion, Enrollment change:  Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia (clinicaltrials.gov) -  Jul 18, 2022   
    P4,  N=11, Completed, 
    However, further clinical studies with a larger population of patients are required to evaluate the clinical significance of ifosfamide-related neurotoxicity and aprepitant or fosaprepitant. Active, not recruiting --> Completed | N=50 --> 11
  • ||||||||||  dexamethasone / Generic mfg., carboplatin / Generic mfg., fosaprepitant / Generic mfg.
    Trial completion date, Trial suspension, Trial primary completion date:  Low Dose Aprepitant for Patients Receiving Carboplatin (clinicaltrials.gov) -  May 25, 2022   
    P2,  N=50, Suspended, 
    The administration of a single dose of fosaprepitant after the induction of anesthesia was as effective as the administration of a single dose of palonosetron for the prophylaxis of vomiting in the first 48 h after surgery in women undergoing laparoscopic cholecystectomy. Trial completion date: Aug 2021 --> Aug 2022 | Recruiting --> Suspended | Trial primary completion date: Jul 2021 --> Jul 2022
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Prolonged usage of fosaprepitant for prevention of delayed CINV in patients receiving highly emetogenic chemotherapy (E-Poster Stage 1, Metropolitan Centre, CC) -  May 22, 2022 - Abstract #MASCCISOO2022MASCC_ISOO_251;    
    No significant difference was found between the two groups regarding constipation, diarrhea, hiccough, fatigue, palpitation and headache in delayed phase. Conclusions Prolonged usage of fosaprepitant was effective and safe in preventing delayed CINV in patients receiving HEC regimens.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Journal:  The crystal structure of the S154Y mutant carbonyl reductase from Leifsonia xyli explains enhanced activity for 3,5-Bis(trifluoromethyl)acetophenone reduction. (Pubmed Central) -  Apr 12, 2022   
    Carbonyl reductase from Leifsonia xyli (LXCAR, UniProtKB - T2FLN4) can stereoselectively catalyze the reduction of 3,5-bis(trifluoromethyl)acetophenone (BTAP) to its corresponding alcohol, (R)-[3,5-bis(trifluoromethyl)phenyl]ethanol ((R)-BTPE), which is a valuable chiral intermediate for the synthesis of antiemetic drugs, Aprepitant and Fosaprepitant...The crystal structure of LXCAR-S154Y explains how the mutant enzyme can work with BTAP more efficiently than wild type carbonyl reductase. Furthermore, the structure explains why LXCAR-S154Y can use either NADH or NADPH efficiently as a cofactor, as well as elucidates a proton relay system present in the enzyme.
  • ||||||||||  dexamethasone / Generic mfg., asenapine / Generic mfg., cisplatin / Generic mfg.
    Preclinical, Journal:  Drug repositioning of antipsychotic drugs for cisplatin-induced pica behavior in mice. (Pubmed Central) -  Mar 19, 2022   
    Three antipsychotics failed to improve the cisplatin-induced decrease in food and water intake, and spontaneous motor activity. The findings suggest that prophylactic administration of antipsychotics besides olanzapine may improve cisplatin-induced nausea and vomiting in a delayed phase and de-escalate standard 3-drug antiemetics.
  • ||||||||||  Varubi (rolapitant oral) / TerSera Therap, GSK
    Retrospective data, Review, Journal:  Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. (Pubmed Central) -  Dec 16, 2021   
    For people receiving HEC, synthesised evidence does not suggest one superior treatment for prevention and control of chemotherapy-induced nausea and vomiting.  For people receiving MEC, synthesised evidence does not suggest superiority for treatments including both NK₁ and 5-HT₃ inhibitors when compared to treatments including 5-HT₃ inhibitors only. Rather, the results of our NMA suggest that the choice of 5-HT₃ inhibitor may have an impact on treatment efficacy in preventing CINV.  When interpreting the results of this systematic review, it is important for the reader to understand that NMAs are no substitute for direct head-to-head comparisons, and that results of our NMA do not necessarily rule out differences that could be clinically relevant for some individuals.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Clinical, Observational data, Journal:  Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study. (Pubmed Central) -  Oct 22, 2021   
    The association with PER polymorphism was not previously reported. Identification of genetic and clinical risk factors for anxiety and depression would help clinicians implement an individualized management therapy aiming at preventing and alleviating the burden of these symptoms in breast cancer patients, hence improving their overall quality of life.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Journal:  Structural insights of human N-acetyltransferase 10 and identification of its potential novel inhibitors. (Pubmed Central) -  Oct 16, 2021   
    Interestingly, Remodelin and others interact with the amino acid residues ILE629, GLY639, GLY641, LEU719, and PHE722 in the Acetyl-CoA binding pocket of NAT10 similar to Acetyl-CoA. Our findings revealed that Fosaprepitant, Leucal, Fludarabine, and Dantrolene are promising molecules that can be tested and developed as potential inhibitors of NAT10 acetyltransferase activity.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Journal:  Modulating Ocular Surface Pain Through Neurokinin-1 Receptor Blockade. (Pubmed Central) -  Oct 3, 2021   
    Topical administration of the NK1R antagonist fosaprepitant effectively reduces ocular surface nociception by decreasing SP release in the tear fluid and TG, and corneal leukocyte infiltration. Fosaprepitant repurposing shows promise for the treatment of ocular pain.
  • ||||||||||  Trial primary completion date:  Proton-PANC: Study of Proton Therapy in Adjuvant Pancreatic Cancer (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=12, Recruiting, 
    Administration of Fos in peripheral veins after AC-based regimen increased ISR. Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  dexamethasone / Generic mfg., cisplatin / Generic mfg.
    Journal:  Evaluation of the Antiemetic Effect of Premedication Optimized by Pharmaceutical Support in Cisplatin Regimens. (Pubmed Central) -  Jul 18, 2021   
    Comparison of the former and revised regimen groups revealed sex (p = 0.012); anticancer drug dosage (p = 0.006); and variation of premedication condition (p = 0.043) as factors affected by the revised regimen. Optimization of the premedication regimen was a form of necessary pharmaceutical support to maintain the patient's QOL.